The current standard of care for CKD focuses on reducing blood pressure (BP) and proteinuria3,4, ideally using renin-angiotensin system antagonists alongside the recent introduction of sodium-glucose co-transporter 2 (SGLT2) inhibitors. This evidence concerns the gene SLC5A2 and chronic kidney disease.